Melasma
Conditions
Interventions
Experimental group:Introduction of tranexamic acid using nanoneedles
Control group:Introduction of tranexamic acid using ultrasound
Sponsors
Guangzhou Dermatosis Prevention and Treatment Institute
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Accord with the expert consensus on the diagnosis and treatment of chloasma in China (2021 version) (Note: Formulated by the Pigmentation Group of Dermatologic and venopathy Professional Committee of Chinese Association of Integrated Traditional and Western Medicine); 2. All patients were female, aged 18-55 years, with a course of disease ranging from 1 to 14 years. The clinical stage was stable, and the clinical classification was buccal type. 3. Subjects are willing to not be directly exposed to sunlight throughout the study period, or to use sunscreen products with SPF > 30 if exposed; 4. The subjects have not used other freckle removal products or received other treatments (such as drugs, chemical exfoliation, laser, etc.) within 1 month before the study; 5. There is no absolute contraindication to tranexamic acid in the treatment of melasma, and they are willing to follow the doctor's arrangement to accept the treatment plan.
Exclusion criteria
Exclusion criteria: 1. Pregnant, expectant or lactating women; 2. Unable to make it to the end of the course; 3. Use other freckle-removing products or receive other treatments (e.g., drugs, lasers, etc.) throughout the study period; 4. The face suffers from herpes simplex or has ulceration, dip, erosion and other skin lesions; 5. People with infectious diseases and mental diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| melasma area andseverity index,MASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Numerical Rating Scale, NRS;Patient satisfaction; | — |
Countries
China
Contacts
Public ContactZhong Jiemin
Guangzhou Dermatosis Preventing & Curing Institute
Outcome results
None listed